Cancer Drug Target Discovery

Key publications

Key publications of the Cancer Drug Target Discovery group

Balcioglu, H.E., B. van de Water, and E.H. Danen. 2016. Tumor-induced remote ECM network orientation steers angiogenesis. Scientific Reports. 6: 22580.
Ghotra, V.P., S. He, G. van der Horst, S. Nijhoff, H. de Bont, A. Lekkerkerker, R. Janssen, G. Jenster, G.J. van Leenders, A.M. Hoogland, E.I. Verhoef, Z. Baranski, J. Xiong, B. van de Water, G. van der Pluijm, B.E. Snaar-Jagalska, and E.H. Danen. 2015. SYK is a candidate kinase target for the treatment of advanced prostate cancer. Cancer Research. 75: 230-240.
Truong, H.H., J. Xiong, V.P. Ghotra, E. Nirmala, L. Haazen, S.E. Le Devedec, H.E. Balcioglu, S. He, B.E. Snaar-Jagalska, E. Vreugdenhil, J.H. Meerman, B. van de Water, and E.H. Danen. 2014. Beta1 integrin inhibition elicits a prometastatic switch through the TGFbeta-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer. Science Signaling. 7: ra15.
Carreras Puigvert, J., L. von Stechow, R. Siddappa, A. Pines, M. Bahjat, L.C. Haazen, J.V. Olsen, H. Vrieling, J.H. Meerman, L.H. Mullenders, B. van de Water, and E.H. Danen. 2013. Systems biology approach identifies the kinase Csnk1a1 as a regulator of the DNA damage response in embryonic stem cells. Science Signaling. 6: ra5.
Truong, H.H., J. de Sonneville, V.P. Ghotra, J. Xiong, L. Price, P.C. Hogendoorn, H.H. Spaink, B. van de Water, and E.H. Danen. 2012. Automated microinjection of cell-polymer suspensions in 3D ECM scaffolds for high-throughput quantitative cancer invasion screens. Biomaterials. 33: 181-188.